{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T23:09:39Z","timestamp":1775257779725,"version":"3.50.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2004,4]]},"DOI":"10.1038\/nrd1346","type":"journal-article","created":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T15:15:51Z","timestamp":1080832551000},"page":"353-359","source":"Crossref","is-referenced-by-count":996,"title":["Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia"],"prefix":"10.1038","volume":"3","author":[{"given":"Bryan L.","family":"Roth","sequence":"first","affiliation":[]},{"given":"Douglas J.","family":"Sheffler","sequence":"additional","affiliation":[]},{"given":"Wesley K.","family":"Kroeze","sequence":"additional","affiliation":[]}],"member":"297","reference":[{"key":"BFnrd1346_CR1","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/nrd964","volume":"1","author":"E Shorter","year":"2002","unstructured":"Shorter, E. Looking backwards: a possible new path for drug discovery in psychopharmacology. Nature Rev. Drug Discov. 1, 1003\u20131006 (2002).","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrd1346_CR2","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0024-3205(97)00662-0","volume":"61","author":"A Carlsson","year":"1997","unstructured":"Carlsson, A. & Wong, D. T. Correction: a note on the discovery of selective serotonin reuptake inhibitors. Life Sci. 61, 1203 (1997).","journal-title":"Life Sci."},{"issue":"Suppl. 12","key":"BFnrd1346_CR3","first-page":"22","volume":"60","author":"H Hippius","year":"1999","unstructured":"Hippius, H. A historical perspective of clozapine. J. Clin. Psychiatry 60 (Suppl. 12), 22\u201323 (1999).","journal-title":"J. Clin. Psychiatry"},{"key":"BFnrd1346_CR4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S0140-6736(03)12379-3","volume":"361","author":"PJ Harrison","year":"2003","unstructured":"Harrison, P. J. & Owen, M. J. Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet 361, 417\u2013419 (2003).","journal-title":"Lancet"},{"key":"BFnrd1346_CR5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1086\/376549","volume":"73","author":"CM Lewis","year":"2003","unstructured":"Lewis, C. M. et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. Am. J. Hum. Genet. 73, 34\u201348 (2003).","journal-title":"Am. J. Hum. Genet."},{"key":"BFnrd1346_CR6","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1124\/mol.64.6.1277","volume":"64","author":"V Setola","year":"2003","unstructured":"Setola, V. & Roth, B. L. Why mice are neither miniature humans nor small rats: a cautionary tale involving 5-hydroxytryptamine-6 serotonin receptor species variants. Mol. Pharmacol. 64, 1277\u20131278 (2003).","journal-title":"Mol. Pharmacol."},{"key":"BFnrd1346_CR7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0896-6273(03)00195-8","volume":"38","author":"JT Coyle","year":"2003","unstructured":"Coyle, J. T. & Duman, R. S. Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron 38, 157\u2013160 (2003).","journal-title":"Neuron"},{"key":"BFnrd1346_CR8","doi-asserted-by":"crossref","unstructured":"Roth, B., Sheffler, D. J. & Potkin, S. Atypical antipsychotic drugs: unitary or multiple mechanisms for 'atypicality'. Clin. Neurosci. Res. (in the press).","DOI":"10.1016\/S1566-2772(03)00021-5"},{"key":"BFnrd1346_CR9","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","volume":"45","author":"J Kane","year":"1988","unstructured":"Kane, J., Honigfield, G., Singer, J., Meltzer, H. Y. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 45, 789\u2013796 (1988).","journal-title":"Arch. Gen. Psychiatry"},{"key":"BFnrd1346_CR10","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1001\/archpsyc.60.1.82","volume":"60","author":"HY Meltzer","year":"2003","unstructured":"Meltzer, H. Y. et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch. Gen. Psychiatry 60, 82\u201391 (2003).","journal-title":"Arch. Gen. Psychiatry"},{"key":"BFnrd1346_CR11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd1062","volume":"2","author":"FC Colpaert","year":"2003","unstructured":"Colpaert, F. C. Discovering risperidone: the LSD model of psychopathology. Nature Rev. Drug Discov. 2, 315\u2013320 (2003).","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrd1346_CR12","first-page":"238","volume":"251","author":"HY Meltzer","year":"1989","unstructured":"Meltzer, H. Y., Matsubara, S. & Lee, J. -C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther. 251, 238\u2013246 (1989).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnrd1346_CR13","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/0361-9230(86)90181-4","volume":"16","author":"CA Altar","year":"1986","unstructured":"Altar, C. A., Wasley, A. M., Neale, R. F. & Stone, G. A. Typical and atypical antipsychotic occupancy of D2 and S2 receptors: an autoradiographic analysis in rat brain. Brain Res. Bull. 16, 517\u2013525 (1986).","journal-title":"Brain Res. Bull."},{"key":"BFnrd1346_CR14","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/S0140-6736(03)13306-5","volume":"361","author":"S Leucht","year":"2003","unstructured":"Leucht, S., Wahlbeck, K., Hamann, J. & Kissling, W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361, 1581\u20131589 (2003).","journal-title":"Lancet"},{"key":"BFnrd1346_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0920-9964(01)00212-2","volume":"56","author":"A Tuunainen","year":"2002","unstructured":"Tuunainen, A., Wahlbeck, K. & Gilbody, S. Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials. Schizophr. Res. 56, 1\u201310 (2002).","journal-title":"Schizophr. Res."},{"key":"BFnrd1346_CR16","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0165-1781(01)00234-7","volume":"101","author":"KR Fontaine","year":"2001","unstructured":"Fontaine, K. R. et al. Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res. 101, 277\u2013288 (2001).","journal-title":"Psychiatry Res."},{"key":"BFnrd1346_CR17","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/sj.npp.1300027","volume":"28","author":"WK Kroeze","year":"2003","unstructured":"Kroeze, W. K. et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28, 519\u2013526 (2003).","journal-title":"Neuropsychopharmacology"},{"key":"BFnrd1346_CR18","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/oxfordjournals.schbul.a033376","volume":"25","author":"HY Meltzer","year":"1999","unstructured":"Meltzer, H. Y. & McGurk, S. R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. 25, 233\u2013255 (1999).","journal-title":"Schizophr. Bull."},{"key":"BFnrd1346_CR19","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1523\/JNEUROSCI.22-07-02843.2002","volume":"22","author":"GV Williams","year":"2002","unstructured":"Williams, G. V., Rao, S. G. & Goldman-Rakic, P. S. The physiological role of 5-HT2A receptors in working memory. J. Neurosci. 22, 2843\u20132854 (2002).","journal-title":"J. Neurosci."},{"key":"BFnrd1346_CR20","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/S0028-3908(01)00056-9","volume":"41","author":"ML Woolley","year":"2001","unstructured":"Woolley, M. L., Bentley, J. C., Sleight, A. J., Marsden, C. A. & Fone, K. C. A role for 5-HT6 receptors in retention of spatial learning in the Morris water maze. Neuropharmacology 41, 210\u2013219 (2001).","journal-title":"Neuropharmacology"},{"key":"BFnrd1346_CR21","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1126\/science.287.5460.2020","volume":"287","author":"SA Castner","year":"2000","unstructured":"Castner, S. A., Williams, G. V. & Goldman-Rakic, P. S. Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. Science 287, 2020\u20132022 (2000).","journal-title":"Science"},{"key":"BFnrd1346_CR22","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/S0165-6147(97)90618-0","volume":"18","author":"LJ Bristow","year":"1997","unstructured":"Bristow, L. J. et al. Schizophrenia and L-745,870, a novel dopamine D4 receptor antagonist. Trends Pharmacol. Sci. 18, 186 (1997).","journal-title":"Trends Pharmacol. Sci."},{"key":"BFnrd1346_CR23","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1176\/ajp.156.3.419","volume":"156","author":"P Truffinet","year":"1999","unstructured":"Truffinet, P. et al. Placebo-controlled study of the D4\/5-HT2A antagonist fananserin in the treatment of schizophrenia. Am. J. Psychiatry 156, 419\u2013425 (1999).","journal-title":"Am. J. Psychiatry"},{"key":"BFnrd1346_CR24","first-page":"123","volume":"2","author":"T de Paulis","year":"2001","unstructured":"de Paulis, T. M-100907 (Aventis). Curr. Opin. Investig. Drugs 2, 123\u2013132 (2001).","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"BFnrd1346_CR25","unstructured":"Meltzer, H., Arvantis, L., Bauer, D., Rein, W. & Group, M. S. A placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry (in the press)."},{"key":"BFnrd1346_CR26","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0920-9964(00)00129-8","volume":"49","author":"T Rasmussen","year":"2001","unstructured":"Rasmussen, T. et al. The muscarinic receptor agonist BuTAC, a novel potential antipsychotic, does not impair learning and memory in mouse passive avoidance. Schizophr. Res. 49, 193\u2013201 (2001).","journal-title":"Schizophr. Res."},{"key":"BFnrd1346_CR27","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/0014-2999(82)90297-7","volume":"83","author":"D Clark","year":"1982","unstructured":"Clark, D. et al. Is 3-PPP a potential antip sychotic agent? Evidence from animal behavioral studies. Eur. J. Pharmacol. 83, 131\u2013134 (1982).","journal-title":"Eur. J. Pharmacol."},{"key":"BFnrd1346_CR28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S0006-3223(97)00030-9","volume":"43","author":"AC Lahti","year":"1998","unstructured":"Lahti, A. C. et al. Antipsychotic properties of the partial dopamine agonist (\u2212)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia. Biol. Psychiatry 43, 2\u201311 (1998).","journal-title":"Biol. Psychiatry"},{"key":"BFnrd1346_CR29","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s007020050091","volume":"105","author":"AC Lahti","year":"1998","unstructured":"Lahti, A. C., Weiler, M., Carlsson, A. & Tamminga, C. A. Effects of the D3 and autoreceptor-preferring dopamine antagonist (+)-UH232 in schizophrenia. J. Neural Transm. 105, 719\u2013734 (1998).","journal-title":"J. Neural Transm."},{"key":"BFnrd1346_CR30","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/0924-977X(95)00022-H","volume":"5","author":"O Benkert","year":"1995","unstructured":"Benkert, O., Muller-Siecheneder, F. & Wetzel, H. Dopamine agonists in schizophrenia: a review. Eur. Neuropsychopharmacol. 5, S43\u2013S53 (1995).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"BFnrd1346_CR31","first-page":"329","volume":"274","author":"T Kikuchi","year":"1995","unstructured":"Kikuchi, T. et al. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-qui nolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J. Pharmacol. Exp. Ther. 274, 329\u2013336 (1995).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnrd1346_CR32","doi-asserted-by":"publisher","first-page":"763","DOI":"10.4088\/JCP.v63n0903","volume":"63","author":"JM Kane","year":"2002","unstructured":"Kane, J. M. et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin. Psychiatry 63, 763\u2013771 (2002).","journal-title":"J Clin. Psychiatry"},{"key":"BFnrd1346_CR33","first-page":"137","volume":"277","author":"T Inoue","year":"1996","unstructured":"Inoue, T., Domae, M., Yamada, K. & Furukawa, T. Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland. J. Pharmacol. Exp. Ther. 277, 137\u2013143 (1996).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnrd1346_CR34","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1124\/jpet.102.033175","volume":"302","author":"KD Burris","year":"2002","unstructured":"Burris, K. D. et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther. 302, 381\u2013389 (2002).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnrd1346_CR35","unstructured":"Hemrick\u2013Luecke, S. et al. Pharmacological activity of aripiprazole at presynaptic and postsynaptic dopamine receptors and in antipsychotic models. Proc. Soc. Neurosci. 894.9 (2002)."},{"key":"BFnrd1346_CR36","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/S0893-133X(98)00099-2","volume":"20","author":"CP Lawler","year":"1999","unstructured":"Lawler, C. P. et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20, 612\u2013627 (1999).","journal-title":"Neuropsychopharmacology"},{"key":"BFnrd1346_CR37","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nrd722","volume":"1","author":"T Kenakin","year":"2002","unstructured":"Kenakin, T. Efficacy at G-protein-coupled receptors. Nature Rev. Drug Discov. 1, 103\u2013110 (2002).","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrd1346_CR38","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/0024-3205(87)90621-7","volume":"41","author":"BL Roth","year":"1987","unstructured":"Roth, B. L. & Chuang, D. M. Multiple mechanisms of serotonergic signal transduction. Life Sci. 41, 1051\u20131064 (1987).","journal-title":"Life Sci."},{"key":"BFnrd1346_CR39","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","volume":"28","author":"DA Shapiro","year":"2003","unstructured":"Shapiro, D. A. et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28, 1400\u20131411 (2003).","journal-title":"Neuropsychopharmacology"},{"key":"BFnrd1346_CR40","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1126\/science.1083328","volume":"301","author":"L Santarelli","year":"2003","unstructured":"Santarelli, L. et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301, 805\u2013809 (2003).","journal-title":"Science"},{"key":"BFnrd1346_CR41","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/bmb\/57.1.161","volume":"57","author":"IM Anderson","year":"2001","unstructured":"Anderson, I. M. Meta-analytical studies on new antidepressants. Br. Med. Bull. 57, 161\u2013178 (2001).","journal-title":"Br. Med. Bull."},{"key":"BFnrd1346_CR42","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1192\/bjp.178.3.234","volume":"178","author":"ME Thase","year":"2001","unstructured":"Thase, M. E., Entsuah, A. R. & Rudolph, R. L. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry 178, 234\u2013241 (2001).","journal-title":"Br. J. Psychiatry"},{"key":"BFnrd1346_CR43","first-page":"42","volume":"4","author":"M Briley","year":"2003","unstructured":"Briley, M. New hope in the treatment of painful symptoms in depression. Curr. Opin. Investig. Drugs 4, 42\u201345 (2003).","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"BFnrd1346_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ajmg.b.20073","volume":"123B","author":"G Zubenko","year":"2003","unstructured":"Zubenko, G. et al. Genome-wide linkage survey for genetic loci that influence the development of depressive disorders in families with recurrent, early-onset, major depression. Am. J. Med Genet. 123B, 1\u201318 (2003).","journal-title":"Am. J. Med Genet."},{"key":"BFnrd1346_CR45","doi-asserted-by":"publisher","first-page":"S107","DOI":"10.1016\/S1359-6446(02)02423-6","volume":"7","author":"D Brunner","year":"2002","unstructured":"Brunner, D., Nestler, E. & Leahy, E. In need of high-throughput behavioral systems. Drug Discov. Today 7, S107\u2013S112 (2002).","journal-title":"Drug Discov. Today"},{"key":"BFnrd1346_CR46","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1126\/science.298.5602.2320","volume":"298","author":"J Bohannon","year":"2002","unstructured":"Bohannon, J. Animal models. Can a mouse be standardized? Science 298, 2320\u20132321 (2002).","journal-title":"Science"},{"key":"BFnrd1346_CR47","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/S0278-5846(02)00298-1","volume":"26","author":"JD Amsterdam","year":"2002","unstructured":"Amsterdam, J. D., Brunswick, D. J. & Hundert, M. A single-site, double-blind, placebo-controlled, dose-ranging study of YKP10A \u2014 a putative, new antidepressant. Prog. Neuropsychopharmacol. Biol. Psychiatry 26, 1333\u20131338 (2002).","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"BFnrd1346_CR48","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/00004850-200111000-00005","volume":"16","author":"JP Feighner","year":"2001","unstructured":"Feighner, J. P. et al. Double-blind, placebo-controlled study of INN 00835 (netamiftide) in the treatment of outpatients with major depression. Int. Clin. Psychopharmacol. 16, 345\u2013352 (2001).","journal-title":"Int. Clin. Psychopharmacol."},{"key":"BFnrd1346_CR49","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2174\/1568007024606203","volume":"1","author":"MG Palfreyman","year":"2002","unstructured":"Palfreyman, M. G. et al. Novel directions in antipsychotic target identification using gene arrays. Curr. Drug Target CNS Neurol. Disord. 1, 227\u2013238 (2002).","journal-title":"Curr. Drug Target CNS Neurol. Disord."},{"key":"BFnrd1346_CR50","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0014-5793(96)00355-9","volume":"385","author":"H Suessbrich","year":"1996","unstructured":"Suessbrich, H., Waldegger, S., Lang, F. & Busch, A. E. Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett. 385, 77\u201380 (1996).","journal-title":"FEBS Lett."},{"key":"BFnrd1346_CR51","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1161\/01.CIR.102.23.2836","volume":"102","author":"RB Rothman","year":"2000","unstructured":"Rothman, R. B. et al. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102, 2836\u20132841 (2000).","journal-title":"Circulation"},{"key":"BFnrd1346_CR52","first-page":"946","volume":"2","author":"G Remington","year":"2001","unstructured":"Remington, G. & Kapur, S. SB-277011 GlaxoSmithKline. Curr. Opin. Investig. Drugs 2, 946\u2013949 (2001).","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"BFnrd1346_CR53","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1001\/archpsyc.1997.01830180085011","volume":"54","author":"MS Kramer","year":"1997","unstructured":"Kramer, M. S., Last, B., Getson, A. & Reines, S. A. The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group. Arch. Gen. Psychiatry 54, 567 (1997).","journal-title":"Arch. Gen. Psychiatry"},{"key":"BFnrd1346_CR54","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/npp.1994.5","volume":"10","author":"GR Gewirtz","year":"1994","unstructured":"Gewirtz, G. R. et al. BMY14802, a \u03c3 receptor ligand for the treatment of schizophrenia. Neuropsychopharmacology 10, 37\u201340 (1994).","journal-title":"Neuropsychopharmacology"},{"key":"BFnrd1346_CR55","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0165-1781(99)00100-6","volume":"89","author":"MJ Muller","year":"1999","unstructured":"Muller, M. J. et al. Antipsychotic effects and tolerability of the sigma ligand EMD 57445 (panamesine) and its metabolites in acute schizophrenia: an open clinical trial. Psychiatry Res. 89, 275\u2013280 (1999).","journal-title":"Psychiatry Res."},{"key":"BFnrd1346_CR56","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/S0006-3223(96)00311-3","volume":"40","author":"B van Berckel","year":"1996","unstructured":"van Berckel, B. et al. Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients. Biol. Psychiatry 40, 1298 (1996).","journal-title":"Biol. Psychiatry"},{"key":"BFnrd1346_CR57","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0920-9964(01)00220-1","volume":"56","author":"AE Evins","year":"2002","unstructured":"Evins, A. E., Amico, E., Posever, T. A., Toker, R. & Goff, D. C. D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophr. Res. 56, 19\u201323 (2002).","journal-title":"Schizophr. Res."},{"key":"BFnrd1346_CR58","doi-asserted-by":"crossref","unstructured":"Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 361, 799\u2013808 (2003).","DOI":"10.1016\/S0140-6736(03)12705-5"},{"key":"BFnrd1346_CR59","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/S0006-3223(02)01425-7","volume":"52","author":"SM Stahl","year":"2002","unstructured":"Stahl, S. M., Entsuah, R. & Rudolph, R. L. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol. Psychiatry 52, 1166\u20131174 (2002).","journal-title":"Biol. Psychiatry"},{"key":"BFnrd1346_CR60","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/S0140-6736(96)08007-5","volume":"349","author":"V Perez","year":"1997","unstructured":"Perez, V., Gilaberte, I., Faries, D., Alvarez, E. & Artigas, F. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 349, 1594\u20131597 (1997).","journal-title":"Lancet"},{"key":"BFnrd1346_CR61","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/S0006-3223(98)00383-7","volume":"45","author":"RM Berman","year":"1999","unstructured":"Berman, R. M. et al. The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial. Biol. Psychiatry 45, 1170\u20131177 (1999).","journal-title":"Biol. Psychiatry"},{"key":"BFnrd1346_CR62","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","volume":"101","author":"DE Nichols","year":"2004","unstructured":"Nichols, D. E. Hallucinogens. Parmacol. Ther. 101, 131\u2013181 (2004).","journal-title":"Parmacol. Ther."},{"key":"BFnrd1346_CR63","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1242\/jcs.00902","volume":"116","author":"WK Kroeze","year":"2003","unstructured":"Kroeze, W. K., Sheffler, D. J. & Roth, B. L. G-protein-coupled receptors at a glance. J. Cell Sci. 116, 4867\u20134869 (2003).","journal-title":"J. Cell Sci."}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrd1346.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrd1346","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrd1346.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:45:46Z","timestamp":1684467946000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrd1346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["BFnrd1346"],"URL":"https:\/\/doi.org\/10.1038\/nrd1346","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,4]]}}}